David Shaw’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

David Shaw’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,600	Closed	-$2.73M	–	6089
2021 Q4	$2.73M	Sell	18,600 -10,800	-37%	-$1.68M	﹤0.01%	3064
2021 Q3	$5.2M	Sell	29,400 -20,000	-40%	-$3.22M	﹤0.01%	2073
2021 Q2	$7.98M	Hold	49,400	–	–	0.01%	1684
2021 Q1	$8.46M	Hold	49,400	–	–	0.01%	1474
2020 Q4	$10.8M	Buy	49,400 +30,700	+164%	+$6.64M	0.01%	1347
2020 Q3	$3.1M	Buy	18,700 +8,700	+87%	+$1.19M	﹤0.01%	2044
2020 Q2	$1.14M	Hold	10,000	–	–	﹤0.01%	2832
2020 Q1	$769K	Hold	10,000	–	–	﹤0.01%	2939
2019 Q4	$1.29M	Buy	+10,000	New	+$965K	﹤0.01%	2801
2019 Q3	–	Sell	-10,000	Closed	-$1.03M	–	4072
2019 Q2	$1.03M	Buy	+10,000	New	+$779K	﹤0.01%	2664

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

David Shaw's MRTX Position: Q1 2024 in Review

David Shaw sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7,693 shares — an estimated $452K sold.

David Shaw first reported a position in MRTX in Q3 2015 and held it in 25 quarters. The position peaked at $39.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

David Shaw reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
David Shaw sold 7,693 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $452K.
David Shaw first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 25 quarters.
David Shaw's Mirati Therapeutics, Inc. Common Stock position peaked at $39.6M in Q3 2022.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.